Current status and clinical outcomes of pharmacotherapies according to SARS-CoV-2 mutations in patients with mild-to-moderate COVID-19: a retrospective single center study

Regdanvimab was primarily used during the ancestral strain period, regdanvimab plus corticosteroids during the Delta variant period, and remdesivir during the Omicron variant period. The rate of death or disease aggravation was highest in the Delta variant, followed by the Omicron variant and the ancestral strain.

Authors

Miran Park (ORCID: https://orcid.org/0000-0003-4986-4072)
Nam Kyung Je (ORCID: https://orcid.org/0000-0002-0299-5131)
Susin Park (ORCID: https://orcid.org/0000-0001-7016-5124)
Jeonghun Heo (ORCID: https://orcid.org/0000-0002-9534-2921)
Dong Wan Kim (ORCID: https://orcid.org/0000-0002-7230-3540)

Institutions

Kyungsung University (KR)
Good Moonhwa Hospital (KR)
Maryknoll Medical Center (KR)
Busan Medical Center (KR)
Pusan National University (KR)

Publication Details

Journal: BMC Infectious Diseases
Published: 2024-09-02
DOI: https://doi.org/10.1186/s12879-024-09765-4
Citations: 1
Primary Topic: COVID-19 Clinical Research Studies
Type: article
Field-Weighted Citation Impact: 0.39

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Current status and clinical outcomes of pharmacotherapies according to SARS-CoV-2 mutations in patients with mild-to-moderate COVID-19: a retrospective single center study

Miran Park, Nam Kyung Je, Susin Park, Jeonghun Heo et al.

Sep 2, 2024

1 citations

BMC Infectious Diseases

COVID-19 Clinical Research Studies

0.39

article

Current status and clinical outcomes of pharmacotherapies according to SARS-CoV-2 mutations in patients with mild-to-moderate COVID-19: a retrospective single center study

Miran Park, Nam Kyung Je, Susin Park, Jeonghun Heo, Dong Wan Kim

September 2, 2024article en

1 citations

Abstract

Regdanvimab was primarily used during the ancestral strain period, regdanvimab plus corticosteroids during the Delta variant period, and remdesivir during the Omicron variant period. The rate of death or disease aggravation was highest in the Delta variant, followed by the Omicron variant and the ancestral strain.

BMC Infectious DiseasesVol. 24(1)

Kyungsung University (KR), Good Moonhwa Hospital (KR), Maryknoll Medical Center (KR), Busan Medical Center (KR), Pusan National University (KR)

Good health and well-being

Openalex Percentile: Top 37%

COVID-19 Clinical Research Studies

0.39

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Current status and clinical outcomes of pharmacotherapies according to SARS-CoV-2 mutations in patients with mild-to-moderate COVID-19: a retrospective single center study — Miran Park, Nam Kyung Je, et al. · BMC Infectious Diseases (2024) | TGRS Research Map | TGRS